An Evaluation of the Effectiveness of a Proprietary Probiotic Blend on Functional Constipation
Primary Purpose
Functional Constipation
Status
Completed
Phase
Phase 2
Locations
Canada
Study Type
Interventional
Intervention
Proprietary Probiotic Blend
Placebo
Sponsored by
About this trial
This is an interventional other trial for Functional Constipation
Eligibility Criteria
Inclusion Criteria:
- Healthy male or female adults, aged 18 to 65 years
- BMI of 18.5 kg/m2 to 35.0 kg/m2 (inclusive)
- Subject is not of child bearing potential. Defined as females who have had a hysterectomy or oophorectomy, bilateral tubal ligation or are post-menopausal (natural or surgically with > 1 year since last menstruation) OR Female subject of childbearing potential must agree to use a medically approved method of birth control and have a negative urine pregnancy test result. Acceptable methods of birth control include:
- Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System)
- Double-barrier method (condoms with spermicide or diaphragm with spermicide)
- Non-hormonal intrauterine devices
- Vasectomy of partner
- Non-heterosexual lifestyle
- Subjects must have at least two of the following criteria based on subject self-reporting, for the past 3 months with the symptoms beginning at least 6 months ago:
Two or more criteria must be met by subjects:
- Straining during at least 25% of defecations
- Lumpy or hard stools in at least 25% of defecations
- Sensation of incomplete evacuation for at least 25% of defecations
- Sensation of anorectal obstruction/blockage for at least 25% of defecations
- Fewer than three defecations per week
- Loose stools are rarely present without the use of laxatives
- Insufficient criteria for Irritable Bowel Syndrome
- Subjects with an average stool type of < 3 on the Bristol Stool Scale as assessed over the two week run-in period (confirmed at baseline review of bowel habits diary).
- Subjects who agree to maintain their current level of physical activity throughout the trial period.
- Subjects who agree to discontinue the use of probiotic supplements including foods supplemented with probiotics (i.e. yogurts) or fiber supplements including foods labeled as supplemented with fiber
- Subjects who agree to discontinue use of over-the-counter laxative medications (other than the rescue medication provided) within 2 weeks of screening and throughout the trial.
- Subjects who successfully complete the run-in period by completing at least 80% of Run-In diary entries, 100% of IPAQ questionnaires and provide fecal sample.
- Subjects who understand the nature and purpose of the study including the potential risks and side effects
- Subjects who are willing to complete all study procedures including study related questionnaires and comply with study requirements
- Subjects who have given voluntary, written, informed consent to participate in the study.
Exclusion Criteria:
- Subjects who are pregnant, breastfeeding or planning on becoming pregnant throughout the course of the study.
- Subjects with any unstable medical conditions
- Subjects with any major diseases of the cardiovascular, renal, hepatic, gastrointestinal, pulmonary or endocrine systems
- Subjects with Type I or Type II diabetes
- Subjects with a history of major gastrointestinal complications (i.e. Crohn's disease, ulcer, cancer, ulcerative colitis)
- History of or current diagnosis of any cancer (except for successfully treated basal cell carcinoma) diagnosed less than 5 years prior to screening. Subjects with cancer in full remission more than 5 years after diagnosis are acceptable
- Subjects with neurological disorders or significant psychiatric illnesses (significance determined by the Qualified Investigator)
- Subjects who are immuno-compromised (HIV positive, on anti-rejection medication, rheumatoid arthritis)
- Subjects with any medical condition or a history of abdominal surgery that is deemed exclusionary by the Qualified Investigator
- Subjects who have features which may suggest a more serious underlying cause of chronic constipation such as rectal bleeding, anemia, abrupt weight loss ( 5kg or more within the past month prior to randomization), gastrointestinal polyps, first degree family history of colorectal cancer.
- Subjects with an active eating disorder
- Subjects who have used an over-the-counter or prescription laxative medication within 2 weeks prior to screening.
- Subjects who have used probiotic or fiber supplements (or probiotic/fiber enriched foods) within 4 weeks prior to screening
- Subjects who have used an antibiotic within 4 weeks prior to screening
- Subjects who have used medications in the investigators opinion known to cause constipation (i.e. opiates) within 4 weeks of screening
- Subjects using Medicinal Marijuana
- Subjects who use illicit drugs or have a history of alcohol or drug abuse within the past 6 months
- Subjects who currently consume greater than 2 standard alcoholic drinks per day.
- Subjects who have participated in a clinical research trial within 30 days prior to randomization.
- Subjects with an allergy or sensitivity to the investigational product ingredient
- Subjects who are cognitively impaired and/or who are unable to give informed consent
- Subjects who have abnormal laboratory results or any other medical or psychological condition which, in the opinion of the Principle Investigator, may adversely affect the subjects' ability to complete the study or its measures or which may pose significant risk to the subject.
Sites / Locations
- KGK Synergize Inc.
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Placebo Comparator
Arm Label
Proprietary Probiotic Blend
Placebo
Arm Description
A proprietary probiotic blend: Lactobacillus acidophilus, Bifidobacterium lactis, Bifidobacterium longum, and Bifidobacterium bifidum at 56.75 mg
The placebo is administered to randomized healthy participants
Outcomes
Primary Outcome Measures
Changes in the symptoms of constipation as measured by the PAC SYM questionnaire
Secondary Outcome Measures
Changes in stool consistency as measured by the Bristol Stool Scale
Changes in stool frequency
Weekly mean Complete Spontaneous Bowel Movements
Changes in quality of life questionnaire score
Changes in microbial composition of feces
Full Information
NCT ID
NCT02418507
First Posted
March 6, 2015
Last Updated
December 12, 2017
Sponsor
KGK Science Inc.
Collaborators
UAS Labs LLC
1. Study Identification
Unique Protocol Identification Number
NCT02418507
Brief Title
An Evaluation of the Effectiveness of a Proprietary Probiotic Blend on Functional Constipation
Official Title
A Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Evaluate the Effectiveness of a Proprietary Probiotic Blend on Functional Constipation
Study Type
Interventional
2. Study Status
Record Verification Date
December 2017
Overall Recruitment Status
Completed
Study Start Date
May 29, 2015 (Actual)
Primary Completion Date
April 1, 2016 (Actual)
Study Completion Date
May 2016 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
KGK Science Inc.
Collaborators
UAS Labs LLC
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The primary objective for this study is to monitor the change in patient assessed symptoms of constipation in subjects taking the proprietary probiotic blend compared to those taking the placebo. The secondary objective for this study is to additionally monitor changes in stool consistency, stool frequency, quality of life and microbial composition of feces from baseline to Day 29, in all subjects. Safety considerations monitored any changes in blood safety parameters as well as incidence of adverse events throughout the entire study for all subjects.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Functional Constipation
7. Study Design
Primary Purpose
Other
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
100 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Proprietary Probiotic Blend
Arm Type
Active Comparator
Arm Description
A proprietary probiotic blend: Lactobacillus acidophilus, Bifidobacterium lactis, Bifidobacterium longum, and Bifidobacterium bifidum at 56.75 mg
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
The placebo is administered to randomized healthy participants
Intervention Type
Dietary Supplement
Intervention Name(s)
Proprietary Probiotic Blend
Intervention Description
A proprietary probiotic blend: Lactobacillus acidophilus, Bifidobacterium lactis, Bifidobacterium longum, and Bifidobacterium bifidum at 56.75 mg
Intervention Type
Other
Intervention Name(s)
Placebo
Intervention Description
The placebo is administered to randomized healthy participants
Primary Outcome Measure Information:
Title
Changes in the symptoms of constipation as measured by the PAC SYM questionnaire
Time Frame
Baseline to Day 29
Secondary Outcome Measure Information:
Title
Changes in stool consistency as measured by the Bristol Stool Scale
Time Frame
Baseline to Day 29
Title
Changes in stool frequency
Description
Weekly mean Complete Spontaneous Bowel Movements
Time Frame
Baseline to Day 29
Title
Changes in quality of life questionnaire score
Time Frame
Baseline to Day 29
Title
Changes in microbial composition of feces
Time Frame
Baseline to Day 29
Other Pre-specified Outcome Measures:
Title
Changes in blood safety parameters
Description
CBC, electrolytes, creatinine, AST, ALT, GGT and bilirubin
Time Frame
Baseline to Day 29
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Healthy male or female adults, aged 18 to 65 years
BMI of 18.5 kg/m2 to 35.0 kg/m2 (inclusive)
Subject is not of child bearing potential. Defined as females who have had a hysterectomy or oophorectomy, bilateral tubal ligation or are post-menopausal (natural or surgically with > 1 year since last menstruation) OR Female subject of childbearing potential must agree to use a medically approved method of birth control and have a negative urine pregnancy test result. Acceptable methods of birth control include:
Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System)
Double-barrier method (condoms with spermicide or diaphragm with spermicide)
Non-hormonal intrauterine devices
Vasectomy of partner
Non-heterosexual lifestyle
Subjects must have at least two of the following criteria based on subject self-reporting, for the past 3 months with the symptoms beginning at least 6 months ago:
Two or more criteria must be met by subjects:
Straining during at least 25% of defecations
Lumpy or hard stools in at least 25% of defecations
Sensation of incomplete evacuation for at least 25% of defecations
Sensation of anorectal obstruction/blockage for at least 25% of defecations
Fewer than three defecations per week
Loose stools are rarely present without the use of laxatives
Insufficient criteria for Irritable Bowel Syndrome
Subjects with an average stool type of < 3 on the Bristol Stool Scale as assessed over the two week run-in period (confirmed at baseline review of bowel habits diary).
Subjects who agree to maintain their current level of physical activity throughout the trial period.
Subjects who agree to discontinue the use of probiotic supplements including foods supplemented with probiotics (i.e. yogurts) or fiber supplements including foods labeled as supplemented with fiber
Subjects who agree to discontinue use of over-the-counter laxative medications (other than the rescue medication provided) within 2 weeks of screening and throughout the trial.
Subjects who successfully complete the run-in period by completing at least 80% of Run-In diary entries, 100% of IPAQ questionnaires and provide fecal sample.
Subjects who understand the nature and purpose of the study including the potential risks and side effects
Subjects who are willing to complete all study procedures including study related questionnaires and comply with study requirements
Subjects who have given voluntary, written, informed consent to participate in the study.
Exclusion Criteria:
Subjects who are pregnant, breastfeeding or planning on becoming pregnant throughout the course of the study.
Subjects with any unstable medical conditions
Subjects with any major diseases of the cardiovascular, renal, hepatic, gastrointestinal, pulmonary or endocrine systems
Subjects with Type I or Type II diabetes
Subjects with a history of major gastrointestinal complications (i.e. Crohn's disease, ulcer, cancer, ulcerative colitis)
History of or current diagnosis of any cancer (except for successfully treated basal cell carcinoma) diagnosed less than 5 years prior to screening. Subjects with cancer in full remission more than 5 years after diagnosis are acceptable
Subjects with neurological disorders or significant psychiatric illnesses (significance determined by the Qualified Investigator)
Subjects who are immuno-compromised (HIV positive, on anti-rejection medication, rheumatoid arthritis)
Subjects with any medical condition or a history of abdominal surgery that is deemed exclusionary by the Qualified Investigator
Subjects who have features which may suggest a more serious underlying cause of chronic constipation such as rectal bleeding, anemia, abrupt weight loss ( 5kg or more within the past month prior to randomization), gastrointestinal polyps, first degree family history of colorectal cancer.
Subjects with an active eating disorder
Subjects who have used an over-the-counter or prescription laxative medication within 2 weeks prior to screening.
Subjects who have used probiotic or fiber supplements (or probiotic/fiber enriched foods) within 4 weeks prior to screening
Subjects who have used an antibiotic within 4 weeks prior to screening
Subjects who have used medications in the investigators opinion known to cause constipation (i.e. opiates) within 4 weeks of screening
Subjects using Medicinal Marijuana
Subjects who use illicit drugs or have a history of alcohol or drug abuse within the past 6 months
Subjects who currently consume greater than 2 standard alcoholic drinks per day.
Subjects who have participated in a clinical research trial within 30 days prior to randomization.
Subjects with an allergy or sensitivity to the investigational product ingredient
Subjects who are cognitively impaired and/or who are unable to give informed consent
Subjects who have abnormal laboratory results or any other medical or psychological condition which, in the opinion of the Principle Investigator, may adversely affect the subjects' ability to complete the study or its measures or which may pose significant risk to the subject.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Tetyana Pelipyagina, MD
Organizational Affiliation
tetyana@kgksynergize.com
Official's Role
Principal Investigator
Facility Information:
Facility Name
KGK Synergize Inc.
City
London
State/Province
Ontario
ZIP/Postal Code
N6A 5R8
Country
Canada
12. IPD Sharing Statement
Learn more about this trial
An Evaluation of the Effectiveness of a Proprietary Probiotic Blend on Functional Constipation
We'll reach out to this number within 24 hrs